Cidara Therapeutics (CDTX) Misses Q2 EPS by 2051c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($20.65), $20.51 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.95 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• Benchmark Electronics (BHE) Tops Q2 EPS by 16c; offers guidance
• Vista Gold Corp (VGZ) Reports Q2 Loss of $0.02
• FICO (FICO) Tops Q3 EPS by 48c; raises guidance